Hansa Biopharma

Hansa Biopharma is an innovative and rapidly growing biopharmaceutical company leveraging its proprietary enzyme technology to develop transformative, potentially life-saving and life-altering immunomodulatory therapies for rare autoimmune diseases, transplant rejection, and cancer. The company’s lead candidate, imlifidase, is an antibody-cleaving enzyme that may potentially enable kidney transplantation in highly sensitized patients. A marketing authorization application is currently under review by the European Medicines Agency. Hansa’s research and development pipeline is advancing the company’s next-generation enzyme technology to develop novel IgG-cleaving enzymes with reduced immunogenicity for repeat dosing in relapsing autoimmune diseases and oncology.